The metastatic outcome depends on the state of disseminated cancer cells (DCCs) leading to overt metastasis or undergoing ...

Graphdiyne Nanosheets Market to grow from USD 17.2 Mn in 2026 to USD 87.0 Mn by 2036 at a 17.6% CAGR. Get segment, region & competitor insights.

Borophene Nanomaterials Market to grow from USD 13.5 Mn in 2026 to USD 75.6 Mn by 2036 at a 18.8% CAGR. Get segment, region & competitor insights.

The Central Consumer Protection Authority (CCPA), under the provisions of the Consumer Protection Act, 2019 and the Consumer ...

72% of patients on highest tulisokibart dose saw 50% or more lesion reduction versus 35% on placebo 41% of patients on highest dose saw 75% lesion reduction versus 15% on placebo Merck bought ...

Merck will present data at the American Academy of Ophthalmology Annual Meeting next month. (Angus Liu/Fierce Pharma) Merck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the ...

Merck stock sits near analyst targets that fall short of $200, yet a compressed fall calendar of FDA decisions and a pivotal cancer vaccine readout could force Wall Street to rethink the entire ...

Patients who received the personalized vaccine alongside Keytruda went longer before their cancer returned, and longer before it spread to distant parts of the body, than patients who received ...

An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the ...

Merck MRK.N and Moderna MRNA.O said on Wednesday a study of a personalized mRNA vaccine combined with the immunotherapy drug Keytruda reduced melanoma skin cancer recurrence and spread compared with ...

Merck & Co. boosted its 2026 sales outlook after strong demand for newer drugs like Winrevair helped to drive revenues higher in the second quarter. Sales will be between $66.3 billion and $67.3 ...

Merck has extended Keytruda's lifecycle by launching subcutaneous Qlex, securing its exclusivity through 2039, and other extensions supporting market confidence. Recent regulatory approvals, promising ...